Asset Intelligence / Hyperliquid Context
HIMS
Market guides and dated reports for HIMS. Browse recent coverage below or use the archive pages to find older articles.
HIMS references 1 share of Hims & Hers Health, Inc. Class A common stock (NYSE: HIMS), quoted in USD. Hims & Hers operates a consumer health and telehealth platform.
Live Structure
Market Status
Loading current market structure…
- Builderxyz
- Categorystock
- Tracked Marketxyz:HIMS
- Latest TweetOpen
No other live markets from this builder in the current screener.
No same-category alternatives are live in the current screener snapshot.
Archive Summary
Latest Archived Thesis
HIMS Reclaims $34 as Options Flow Front-Runs the July Peptide Decision
HIMS is back at $34.08, up 11.37% over 24 hours, with no fresh company headline behind the move — the tape read as bullish options flow carrying the stock into a known July catalyst. The fundamental cover comes from Barclays, which lifted its target to $39 from $29 last week on a clear inflection in the GLP-1 weight-loss business: May website traffic ran 35% higher year-over-year and monthly app users climbed 21%. Six weeks after bleeding to $24.93 on the Q1 miss, the bull case that got pushed out is being repriced. The real prize is July 23-24, when an FDA advisory committee votes on whether seven peptides join the 503A compounding list — Hims' next product category if it clears.
Archive
HIMS Article Archive
HIMS Reclaims $34 as Options Flow Front-Runs the July Peptide Decision
HIMS is back at $34.08, up 11.37% over 24 hours, with no fresh company headline behind the move — the tape read as bullish options flow carrying the stock into a known July catalyst. The fundamental cover comes from Barclays, which lifte…
HIMS Slides Another 9% as JP Morgan, BofA, Jefferies Cut Targets After Q1 Miss
HIMS is extending its post-earnings slide into the cash session, down another 9.02% to $24.93 as JP Morgan, BofA, and Jefferies all cut price targets in the wake of the Q1 miss. The 2026 EBITDA guide was reduced by $25 million at both en…
HIMS Posts $92M Q1 Loss as Branded GLP-1 Shift Craters Margins
HIMS reported a $92.1 million net loss on $608.1 million of Q1 revenue, missing on the top line and printing -$0.40 EPS against the $0.03 profit consensus. Gross margin compressed 800 basis points to 65% as the company absorbed branded W…
HIMS Slides 8% Into Tonight's Q1 Print as Friday's Squeeze Unwinds
HIMS is down 8.17% to $28.73 hours before Hims & Hers reports Q1 2026 after the close. Consensus has been sitting at $0.03 EPS for weeks, an 85% collapse from last year's $0.20, with revenue growth decelerating to roughly 5% versus 111% …
HIMS Rips 18% Into Q1 Earnings as the GLP-1 Squeeze Stacks Another Leg
HIMS added 18% over 24 hours to $31.24 with the Q1 2026 print landing Monday after the close. Three re-rating events have stacked into the same binary: JPMorgan's late-April Overweight initiation at $35, the Novo Nordisk settlement that …
HIMS Adds 6.74% as RFK Jr. Pushes FDA to Unwind 12 Restricted Peptides
Hims & Hers extended its squeeze on April 16 after HHS Secretary Robert F. Kennedy Jr. said the FDA will pull 12 wellness peptides out of Category 2 restrictions and send them to the Pharmacy Compounding Advisory Committee for review in …
HIMS Squeezes Through the 200-Week Moving Average With 46% of Float Short
Hims & Hers ripped 14% on April 15 with no single headline catalyst. The setup told the story: 85 million shares short — 46% of float — and a technical breakout above the 200-week moving average that started Sunday triggered a cascade of…
How to Trade HIMS on Hyperliquid
Hims & Hers Health is the largest direct-to-consumer telehealth platform in the US, connecting millions of subscribers to licensed providers for treatments spanning weight loss, hair care, sexual health, and mental wellness. HIMS is now …
Background reading selected from this asset's symbol, builder context, and archived catalyst coverage.
HIP-3 Explained: Builder-Deployed Perps on Hyperliquid
HIP-3 lets anyone deploy a perpetual futures market on Hyperliquid — no approval, no gatekeepers. Builder mechanics, fees, and live markets.
Funding Rates Explained: A Trader's Guide (2026)
Funding rates decide if you pay or earn holding a perp position. How Hyperliquid's hourly funding works, reading rate signals, and cash-and-carry arbitrage.